Chris Bunka, CEO of Lexaria Bioscience shares their DehydraTECH technology

“Lexaria Bioscience has the actual opportunity of changing the world. We can do it through saving lives, making health improvements for any number of people. Thus for the one who are ingesting any number of drugs and molecules like pain relief, cannabinoids and nicotine. Everybody knows that smoking is not healthy. Therefore our technology allows for the delivery of drug molecules through ingesting all means. Things that you swallow and that could be a pill, could be a syrup or it could be a cup of coffee. Therefore that technology is called the DehydraTECH. Thus is optimized to carry that drug across the intestinal wall and get more of it into your bloodstream more quickly than it otherwise could. Therefore we’ve tested it in vitro in vivo and in human clinical studies. We’re partnering with companies that can help us do it in America and elsewhere in the world. We actually have seven different R&D projects that we’re launching in the first half of 2019. We’re also continuing to work on our patent portfolio. We have 10 patents granted already and over 50 more that are pending. If we are able to help change the consumption habits of even 1 percent of the global marketplace who smoke, we could save 60,000 thousand lives a year.” – Chris Bunka, CEO of Lexaria Bioscience.

What Lexaria Bioscience Corp. has developed?

Lexaria Bioscience Corp. has developed
They have out-licenses its disruptive and cost-effective DehydraTECH™ technology. Thus promoting
  • Healthier administration methods
  • Lower overall dosing
  • Higher effectiveness of ingestible drugs and other beneficial molecules.

Lexaria’s patented technology, DehydraTECH™ delivers these important benefits:

  • Masks taste/odor
    Eliminates the strong tastes of lipophilic compounds, without the need for unwanted sugar.
  • Reduces time of onset
    Thus effects are felt within 15-20 min vs. 60-120 min.
  • Avoids first-pass liver metabolism – In general initial testing evidences that DehydraTECH may deliver ingested molecules. Particularly with the help of lymphatic system. Instead subjected to “first pass” liver exposure. Therefore mitigating unwanted side effects and reducing liver biotransformation.
  • Increases bio-absorption
    Bio-absorption increases up to 3 – 10X, to equate or exceed that of other routes of administration like inhalational delivery.

For more information on Lexaria Bioscience Corp. (LXX:CSE, NASDAQ: LEXX) please fill out the form below.

Request Investor Info